MBOW Public Output v3.5-p1
CCK CONSOLIDATED HOLDINGS BERHAD
Current Price
1.230
Core Conclusion
目前属于“高位横盘后的弱修复阶段”。
大结构仍未完全破坏，但短线动能已经明显降温。现在不是主升浪，而是处于趋势减速后的方向选择区。1.20–1.25 将决定后面是重新启动，还是进入更深回调。
Structure Analysis
月线层面，长期趋势仍存在。
价格仍守在长期云层上方，OBV高位稳定，说明大资金没有完全撤退。但MACD长期下行，代表主升浪速度已经结束，目前进入长期整理结构。
3个月线层面，趋势进入降速。
MACD高位回落，Fisher下压，OBV开始横盘，说明前期强趋势已经转入整理阶段。好消息是结构尚未崩坏。
周线层面，属于弱修复。
价格多次尝试站回 1.25 上方但失败，MACD接近零轴，OBV偏弱，说明资金观望明显。
日线层面，短线偏弱。
MACD死叉后仍未重新强化，OBV持续回落，说明买盘动力不足。目前只是技术性反弹，不算重新启动。
4H层面，短线尝试止跌。
价格开始回稳，但MACD仍在弱区，OBV没有明显资金回流，因此只能定义为“跌后稳定”，不是正式反转。
Multi-Timeframe Rating
Long-Term Rating
Monthly Rating
B+
Weekly Rating
B-
Long-Term Structure Rating
B
Short-Term Rating
Daily Rating
C+
4H Rating
C+
30min Rating
C+（弱反弹）
Short-Term Structure Rating
C+
Composite Rating
Overall Structure Rating
B-
SPD
4.9 / 10
Key Price Levels
Support Zone
1.200–1.220
当前核心短线支撑。
1.150–1.180
中期结构防守区。
Resistance Zone
1.250–1.280
当前主要压力区。
1.350
重新恢复强趋势的重要关口。
Path A / B / C Scenarios
Path A
重新站稳 1.25 并挑战 1.28
Probability
35%
需要量能回升与MACD重新转强。
Path B
继续在 1.20–1.25 横盘整理
Probability
45%
目前最可能路径。
Path C
跌破 1.20 后进入更深调整
Probability
20%
若OBV继续流失，结构会进一步降级。
Final Verdict
CCK 当前最准确定义：
高位整理中的弱修复结构。
长期结构还没坏，但短线已经明显失去主升浪动能。除非重新站稳 1.25–1.28，否则暂时更像整理股，而不是趋势扩张股。
综合结构评级
B-
SPD
4.9 / 10
重点观察：
1.20 能否持续守稳
1.25 能否重新突破
OBV 是否重新回升
免责声明
以上内容仅用于教育与市场结构讨论，不构成任何买卖建议、投资建议或未来走势保证。所有交易决策应自行研究，并自行承担风险。
MBOW Public Output v3.5-p1
CCK CONSOLIDATED HOLDINGS BERHAD
Current Price
1.230
Core Conclusion
CCK is currently in a weak recovery phase after high-level consolidation.
The larger structure is still intact, but short-term momentum has cooled significantly. This is no longer a strong expansion trend. The 1.20–1.25 zone will determine whether the stock can restart higher or enter a deeper correction.
Structure Analysis
Monthly chart still holds a long-term bullish structure.
Price remains above the long-term cloud and OBV is stable, suggesting major funds have not fully exited. However, MACD continues slowing, showing that the previous strong expansion phase has already faded.
Quarterly structure shows trend deceleration.
MACD is rolling over from elevated levels while OBV begins flattening. This suggests consolidation rather than trend expansion.
Weekly chart remains weak.
Price repeatedly fails near 1.25, while MACD and OBV remain soft. Market participation is currently cautious.
Daily chart is still weak.
MACD remains under pressure after a bearish crossover and OBV continues declining. Current rebound is technical stabilization rather than a true restart.
4H chart shows temporary stabilization.
Price is trying to hold support, but momentum indicators remain weak.
Multi-Timeframe Rating
Long-Term Rating
Monthly Rating
B+
Weekly Rating
B-
Long-Term Structure Rating
B
Short-Term Rating
Daily Rating
C+
4H Rating
C+
30min Rating
C+ (Weak Rebound)
Short-Term Structure Rating
C+
Composite Rating
Overall Structure Rating
B-
SPD
4.9 / 10
Key Price Levels
Support Zone
1.200–1.220
Main short-term support.
1.150–1.180
Mid-term defense zone.
Resistance Zone
1.250–1.280
Primary resistance region.
1.350
Major recovery trigger level.
Path A
Reclaim 1.25 and challenge 1.28
Probability
35%
Requires stronger volume and momentum recovery.
Path B
Continue consolidating between 1.20–1.25
Probability
45%
Currently the most likely scenario.
Path C
Break below 1.20 and enter deeper correction
Probability
20%
Further OBV weakness would downgrade the structure.
Final Verdict
CCK is best defined as:
A weak recovery structure inside high-level consolidation.
Long-term structure is not broken yet, but the stock has clearly lost its previous expansion momentum. Unless price can reclaim 1.25–1.28, it behaves more like a consolidation stock rather than a strong trend continuation name.
Overall Structure Rating
B-
SPD
4.9 / 10
Key focus:
Whether 1.20 can hold
Whether 1.25 can be reclaimed
Whether OBV starts recovering again
Disclaimer
This analysis is for educational and market-structure discussion only. It is not financial advice, not a buy or sell recommendation, and does not guarantee future price movement. Always do your own research and manage risk accordingly.